Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced receiving clinical trial approval in China for its antibody drug conjugate (ADC), 7MW3711, which targets B7-H3. This ADC is set to be assessed as a potential treatment for advanced solid tumors.
B7-H3’s Role in Cancer and 7MW3711’s Mechanism
B7-H3 is a member of the B7 ligand family, known for its overexpression in most cancer types while being present at low levels in normal tissues. It plays a role in inhibiting tumor antigen-specific immune responses in malignant tissues, contributing to the primary effects of cancer progression. Additionally, B7-H3 is implicated in promoting migration, invasion, angiogenesis, chemotherapy resistance, and altering tumor cell metabolism.
Upon injection, 7MW3711 can bind to antigens on the surface of tumor cells and internalize into the cells. Through specific enzymatic hydrolysis, small molecule cytotoxic drugs are released, enabling precise tumor cell killing.
IDDC Technology Platform and Mabwell’s Pipeline
IDDC is a next-generation ADC fixed-point coupling technology platform independently developed by Mabwell. It comprises multiple systematic core patented technologies, including fixed-point coupling process DARfinity, fixed-point connector IDconnect, new loaded molecule Mtoxin, and conditional release structure LysOnly. This platform has been validated in multiple investigational products. Notably, 9MW2921, an ADC targeting Trop-2, has been approved for study in advanced solid tumors, further demonstrating the potential of Mabwell’s IDDC technology in the development of novel cancer treatments.-Fineline Info & Tech
